Pharmaceutical Partnership: CStone – Jiangsu Hengrui

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region CStone will retain the rights to develop and commercialize anti-CTLA-4 mAb […]

STL.News – States Top Leading News